Skip to main content

Table 3 Adverse event and grading for individuals in the CC-486 arm that received at least one dose of medication

From: A randomized, phase II trial of oral azacitidine (CC-486) in patients with resected pancreatic adenocarcinoma at high risk for recurrence

Adverse Event Type

Grade 1 # events (# patients)

Grade 2# events (# patients)

Grade 3# events (# patients)

Grade 4# events (# patients)

Any Grade# events (# patients)

Summary for each grade

Counts

76 (23)

25 (12)

9 (4)

5 (3)

115 (23)

Events/month*

0.49

0.16

0.06

0.03

0.75

Summary by AE type

Constitutional

     

 Appetite/weight loss

12 (11)

0

0

0

12 (11)

 Dizziness

3 (3)

0

0

0

3 (3)

 Fatigue

11 (10)

6 (6)

0

0

17 (13)

 Headache

1 (1)

0

0

0

1 (1)

Gastrointestinal

  

0

0

 

 Abdominal Discomfort/Bloating

3 (3)

1 (1)

0

0

4 (4)

 Constipation

2 (2)

1 (1)

0

0

3 (3)

 Diarrhea

12 (10)

1 (1)

2 (1)

0

15 (10)

 Nausea

17 (12)

4 (2)

0

0

21 (13)

 Dyspepsia

1 (1)

0

0

0

1 (1)

 Flatulence

3 (3)

0

0

0

3 (3)

 Vomiting

2 (2)

2 (2)

0

0

4 (3)

Hematologic

     

 Anemia

3 (3)

2 (2)

2 (1)

0

7 (5)

 Leukopenia

1 (1)

4 (4)

3 (3)

1 (1)

9 (6)

 Lymphocytopenia

0 (0)

0 (1)

1 (1)

0 (0)

1 (1)

 Neutropenia

0

2 (2)

1 (1)

4 (3)

7 (5)

 Thrombocytopenia

1 (1)

2 (1)

0

0

3 (1)

Other

     

 Fever

1 (1)

0

0

0

1 (1)

 Hyperglycemia

1 (1)

0

0

0

1 (1)

 Muscle cramps

1 (1)

0

0

0

1 (1)

 Oral abscess

1 (1)

0

0

0

1 (1)

  1. *Rate per month is based upon a total follow-up of 153.7 months across all patients